Radiopharm Theranostics Ltd (ASX:RAD) CEO Riccardo Canevari speaks with Proactive after the company completed a positive pre-Investigational New Drug (IND) meeting with the US Food and Drug Administration (FDA) for its proprietary imaging agent, F18-pivalate (RAD 101). He says it’s a significant milestone towards Radiopharm’s IND application for late-stage clinical trials. In October 2022, positive data from the Imperial College of London’s Phase IIa imaging trial of RAD 101 in patients with brain metastases showed significant tumour uptake consistent with and independent from the tumour of origin.
Radiopharm welcomes positive guidance from FDA to advance Pivalate
